Asian Pacific Journal of Cancer Prevention

  • 제15권6호
  • /
  • Pages.2465-2472
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Survival Results and Prognostic Factors in T4 N0-3 Non-small Cell Lung Cancer Patients According to the AJCC 7th Edition Staging System

  • Arslan, Deniz (Department of Clinical Oncology, Akdeniz University Faculty of Medicine) ;
  • Bozcuk, Hakan (Department of Clinical Oncology, Akdeniz University Faculty of Medicine) ;
  • Gunduz, Seyda ;
  • Tural, Deniz (Department of Clinical Oncology, Necmetin Erbakan Faculty of Medicine) ;
  • Tattli, Ali Murat (Department of Clinical Oncology, Akdeniz University Faculty of Medicine) ;
  • Uysal, Mukremin (Department of Clinical Oncology, Akdeniz University Faculty of Medicine) ;
  • Goksu, Sema Sezgin (Department of Clinical Oncology, Akdeniz University Faculty of Medicine) ;
  • Bassorgun, Cumhur Ibrahim (Department of Clinical Pathology, Akdeniz University Faculty of Medicine) ;
  • Koral, Lokman (Department of Clinical Oncology, Necmetin Erbakan Faculty of Medicine) ;
  • Coskun, Hasan Senol (Department of Clinical Oncology, Akdeniz University Faculty of Medicine) ;
  • Ozdogan, Mustafa (Department of Clinical Oncology, Akdeniz University Faculty of Medicine) ;
  • Savas, Burhan (Department of Clinical Oncology, Akdeniz University Faculty of Medicine)
  • 발행 : 2014.03.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The American Joint Committee on Cancer (AJCC) published a new staging system ($7^{th}$ edition) in 2009. In our study, we evaluated the survival results and prognostic factors among T4 local advanced non-small cell lung cancer (LA-NSCLC) patients in a large heterogeneous group, in accordance with this new system. Materials and Methods: We retrospectively evaluated the files of 122 T4 N0-3 M0 LA-NSCLC patients, identified according to the new staging system, treated at two centers between November 2003 and June 2012. Variables correlating with univariate survival at p<0.20 were later included in multivariate Cox regression analysis. Here, selection of relevant predictors of survival was carried out in accordance with the likelihood ratio formula with p<0.05 regarded as significant. Results: The median age was 60 and the median follow-up period was 17.4 months. Median overall survival (OS) was 18.3 months, the 1 year overall survival (OS) rate was 72%, and the 5 year OS rate was 28%. Statistically significant predictors of survival were (p<0.20) ECOG-PS (Eastern Cooperative Oncology Group Performance Status), age, T4 factor subgroup, stage and primary treatment in OS univariate analysis. On multivariate analysis for OS ECOG-PS (p=0.001), diagnostic stage (p=0.021), and primary treatment (p=0.004) were significant. In the group receiving non-curative treatment, the median OS was 11.0 months, while it was 19.0 months in the definitive RT group and 26.6 months in the curative treatment group. There was a significant difference between the non-curative group and the groups which had definitive RT and curative operations (respectively p<0.001 and p=0.001) in terms of OS, but not between the groups which had definitive RT and curative operations. The median event free survival (EFS) rate was 9.9 months, with rates of 46% and 19% at 3 and 5 years, respectively. On univariate analysis of EFS rate with ECOG-PS, weight loss and staging, statistical significance was found only for thorax computerized tomography (CT)+18F-fluorodeoxy-glucose positron emission tomography-CT (PET-CT) use, stage and primary treatment (p<0.20). In multivariate analysis with EFS, only the primary treatment was statistically significant (p=0.001). In the group receiving non-curative treatment, the median EFS was 10.5 months while in the curative operation group it was 14.7 months. When all the primary treatment groups were taken into consideration, grade III/IV side effect swas observed in 57 patients (46.6%). Esophagitis was most prominent among those that received definitive radiotherapy. Conclusions: Independent prognostic factors among these 122 heterogeneous LA-NSCLC T4 N0-3 M0 patients were age at diagnosis, ECOG-PS, stage and primary treatment, the last also being a significant prognostic indicator of EFS. Our findings point to the importance of appropriate staging and a multidisciplinary approach with modern imaging methods in this patient group. In those with T4 lesions, treatment selection and the effective use of curative potential should be the most important goal of clinical care.

키워드

참고문헌

  1. Akira I, Kenzo H, Yasumitsu M, et al (2010). Predictors of postoperative survival in patients with locally advanced non-small cell lung carcinoma. Surg Today, 40, 725-8. https://doi.org/10.1007/s00595-009-4127-1
  2. Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1991). Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group Experience. J Clin Oncol, 9, 1618-26.
  3. Albain KS, Swann RS, Rusch VW et al (2009). Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet, 374, 379-86. https://doi.org/10.1016/S0140-6736(09)60737-6
  4. Anne ST, Diane LJ, Jack L, et al (2006). Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer, 106, 2428-36. https://doi.org/10.1002/cncr.21884
  5. Belani CP, Choy H, Bonomi P, et al (2005). Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomised phase II locally advanced multi-modality protocol. J Clin Oncol, 23, 5883-91. https://doi.org/10.1200/JCO.2005.55.405
  6. Benedict D, Michael E, Allan W, et al (2011). Impact of neoadjuvant chemoradiotherapy followed by surgical resection on node-negative T3 and T4 non-small cell lung cancer. J Thorac Cardiovasc Surg, 141, 1392-7. https://doi.org/10.1016/j.jtcvs.2010.12.011
  7. Bernard A, Bouchot O, Hagry O, Favre JP (2001). Risk analysis and long-term survival in patients undergoing resection of T4 lung cancer. Eur J Cardiothorac Surg, 20, 344-9. https://doi.org/10.1016/S1010-7940(01)00788-6
  8. Bhaskarapillai B, Kumar SS, Balasubramanian S (2012). Lung cancer in Malabar Cancer Center in Kerala - a descriptive analysis. Asian Pac J Cancer Prev, 13, 4639-43. https://doi.org/10.7314/APJCP.2012.13.9.4639
  9. Birim O, Kappetein AP, Van Klaveren RJ, Bogers A (2006). Prognostic factors in non-small cell lung cancer surgery. EJSO, 32, 12-23. https://doi.org/10.1016/j.ejso.2005.10.001
  10. Buccheri GF (1991). Chemotherapy and survival in non-small cell lung cancer: the old vexata questo. Chest, 99, 1328-9. https://doi.org/10.1378/chest.99.6.1328
  11. Bulzebruck H, Bopp R, Drings P, et al (1992). New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer, 70, 1102-10. https://doi.org/10.1002/1097-0142(19920901)70:5<1102::AID-CNCR2820700514>3.0.CO;2-5
  12. Capewell S, Sudlow MF (1990). Performance and prognosis in patients with lung cancer. Thorax, 45, 951-6. https://doi.org/10.1136/thx.45.12.951
  13. Cerfolio RJ, Ojha B, Bryant AS et al (2003). The role of FDGPET scans in staging patients with nonsmall cell carcinoma. Ann Thorac Surg, 76, 861-6. https://doi.org/10.1016/S0003-4975(03)00888-9
  14. Charloux A, Hedelin G, Dieteman A, et al (1997). Prognostic value of histology in patients with non-small cell lung cancer. Lung Cancer, 17, 123-34. https://doi.org/10.1016/S0169-5002(97)00655-7
  15. Curan WJ, Paulus R, Langer CJ, et al (2011). Sequential vs concurrent chemoradiation for stage III non-small-cell lung cancer: randomised phase III trial RTOG 9410. J Natl Cancer Inst, 103, 1452-60. https://doi.org/10.1093/jnci/djr325
  16. Detterbeck FC, Boffa DJ, Tanoue LT (2009). The new lung cancer staging system. Chest, 136, 260-1. https://doi.org/10.1378/chest.08-0978
  17. DiPerna CA, Wood DE (2005). Surgical management of T3 and T4 lung cancer. Clin Cancer Res, 11, 5038-44. https://doi.org/10.1158/1078-0432.CCR-05-9007
  18. Dwamena BA (1999). Metastases from NSCLC: Mediastinal staging in the 1990s-Meta-analytic comparison of PET and CT. Radiology, 213, 530-6. https://doi.org/10.1148/radiology.213.2.r99nv46530
  19. Feld F, Borges M, Giner V, et al (1994). Prognostic factors in non-small cell lung cancer. Lung Cancer, 11, 19-23.
  20. Feld R, Abratt R, Graziona S, et al (1997). Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Consensus report. Lung Cancer, 17, 3-10. https://doi.org/10.1016/S0169-5002(97)00637-5
  21. Filippo L, Alfredo C, Stefano M, et al (2012). Induction therapy followed by surgery for T3-T4/N0 non-small cell lung cancer: long-term results. Ann Thorac Surg, 93, 1633-40. https://doi.org/10.1016/j.athoracsur.2012.01.109
  22. Gandara DR, Chansky K, Albain KS, et al (2006). Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin. Lung Cancer, 8, 116-21. https://doi.org/10.3816/CLC.2006.n.039
  23. Globocan 2008. Available at: http://globocan.iarc.fr/. (Last accessed: July.8.2012).
  24. Gregory MM (2012). Cleveland Clinic J Medicine, 79, 32-7.
  25. Hana NH, Neubauer M, Ansari R, et al (2007). Phase III trial of cisplatin plus etoposide plus concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: J Clin Oncol, 25, 7512.
  26. Hao-Xian Y, Xue H, Peng L, et al (2009). Survival and risk factors of surgically treated mediastinal invasion t4 nonsmall cell lung cancer. Ann Thorac Surg, 88, 372-9. https://doi.org/10.1016/j.athoracsur.2009.04.018
  27. Hsu CP, Hsu NY, Chen CY, et al (1996). Surgical experience in treating T4 lung cancer: its resectability, morbidity, mortality and prognosis. Eur J Surg Oncol, 22, 171-6. https://doi.org/10.1016/S0748-7983(96)90775-1
  28. Hsu CP, Hsu NY, Chen CY (1996). Surgical experience in treating T4 lung cancer: its resectability, morbidity, mortality and prognosis. Eur J Surg Oncol, 22, 171-6. https://doi.org/10.1016/S0748-7983(96)90775-1
  29. Inal A, Kaplan MA, Kucukoner M, et al (2012). Prognostic factors for second-line treatment of advanced non-small-cell lung cancer: retrospective analysis at a single institution. Asian Pac J Cancer Prev, 13, 1281-4. https://doi.org/10.7314/APJCP.2012.13.4.1281
  30. Izbicki JR, Knoefel WT, Passlick B, et al (1995). Risk analysis and long-term survival in patients undergoing extended resection of locally advanced lung cancer. J Thorac Cardiovasc Surg, 110, 386-95. https://doi.org/10.1016/S0022-5223(95)70235-0
  31. Jett JR, Scott WT, Rivera MP, et al (2003). Guidelines on treatment of stage IIIB non-small-cell lung cancer. Chest, 123, 221-5. https://doi.org/10.1378/chest.123.1_suppl.221S
  32. Jian L, Chun-Hua D, Li-Chao Y, et al (2009). Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer. Clin Lung Cancer, 10, 353-9. https://doi.org/10.3816/CLC.2009.n.048
  33. Kazuhiko S, Shinichi T, Katsuyuki K, et al (2012). Induction chemoradiotherapy followed by surgical resection for clinical T3 or T4 locally advanced non-small cell lung cancer. Ann Surg Oncol, 19, 2685-92. https://doi.org/10.1245/s10434-012-2302-x
  34. Lucchi M, Viti A, Melfi F, et al (2007). IIIB-T4 non-small cell lung cancer: indications and results of surgical treatment. J Cardiovasc Surg (Torino), 48, 369-74 .
  35. Malik PS, Sharma MC, Mohanti BK, et al (2013). Clinicopathological profile of lung cancer at AIIMS: a changing paradigm in India. Asian Pac J Cancer Prev, 14, 489-94 . https://doi.org/10.7314/APJCP.2013.14.1.489
  36. Marino P, Pampallona S, Preatoni A, et al (1994). Chemotherapy vs supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature. Chest, 106, 861-5.
  37. Martini N, Yellin A, Ginsberg RJ, et al (1994). Management of non-small cell lung cancer with direct mediastinal involvement. Ann Thorac Surg, 58, 1447-51. https://doi.org/10.1016/0003-4975(94)91933-X
  38. Martins SJ, Pereira JR (1999). Clinical factors and prognosis in non-small cell lung cancer. Am J Clin Oncol, 22, 453-7. https://doi.org/10.1097/00000421-199910000-00006
  39. Maruf S, Ahmet FI, Bulent T, et al (2009). The outcome of surgery and prognostic factors in patients with t4 non-small cell lung cancer. Turkey Clinics J Med Sci, 29, 420-8.
  40. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981). Reporting results of cancer treatment. Cancer, 47, 207-14. https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
  41. Mutlu H, Buyukcelik A, Erden A, et al (2013). Staging with PET-CT in patients with locally advanced non small cell lung cancer is superior to conventional staging methods in terms of survival. Asian Pac J Cancer Prev, 14, 3743-6. https://doi.org/10.7314/APJCP.2013.14.6.3743
  42. Nael AS, Kathy G, Julie L, et al (2008). Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. Eur J Cardiothoracic Surgery, 34, 892-7. https://doi.org/10.1016/j.ejcts.2008.07.023
  43. Necla S, Bekir K, Ugur O, et al (2005). Prognostic factors affecting the survival on advanced stage non-small-cell lung cancer. Thorax Magazine, 6, 91-7.
  44. Okamato T, Maruyama R, Asoh H, et al (2005). Long term survivors in stage IV non-small cell lung cancer. Lung Cancer, 47, 85-91. https://doi.org/10.1016/j.lungcan.2004.06.006
  45. Osaki T, Sugio K, Hanagiri T, et al (2003). Survival and prognostic factors of surgically resected T4 non-small cell lung cancer. Ann Thorac Surg, 75, 1745-51. https://doi.org/10.1016/S0003-4975(03)00037-7
  46. Paesmans M, Sculier JP, Libert P, et al (1995). Prognosic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. The European Lung Cancer Working Party. J Clin Oncol, 13, 1221-30.
  47. Parkin DM, Pisani P, Ferlay J (1999). Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer, 80, 827-41. https://doi.org/10.1002/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P
  48. Pater JL, Loeb M (1982). Nonanatomic prognostic factors in carcinoma of the lung: a multivariate analyses. Cancer, 50, 326-31. https://doi.org/10.1002/1097-0142(19820715)50:2<326::AID-CNCR2820500227>3.0.CO;2-G
  49. Pierre F, Gilles R, Pascal T, et al (2005). Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small- cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo- Cancerologie NPC 95-01 Study. J Clin Oncol, 23, 5910-7. https://doi.org/10.1200/JCO.2005.03.070
  50. Pitz CC, Brutel de la Riviere A, van Swieten HA, et al (2003). Results of surgical treatment of T4 non-small cell lung cancer. Eur J Cardiothorac Surg, 24, 1013-8. https://doi.org/10.1016/S1010-7940(03)00493-7
  51. Prager D, Cameron R, Ford J, et al (2000). Textbook of respiratory medicine 3th ed. Philadelphia: W.B. Saunders, 1415-45.
  52. Reboul FL(2004). Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data. Hematol Oncol Clin North Am, 18, 41-53. https://doi.org/10.1016/S0889-8588(03)00138-2
  53. Reed CE, Harpole DH, Posther KE, et al (2003). Results of the American college of surgeons oncology group Z0050 trial: the utility of positron emission tomography in staging potentially operable nonsmall cell lung cancer. J Thorac Cardiovasc Surg, 126, 1943-51. https://doi.org/10.1016/j.jtcvs.2003.07.030
  54. Ruchdeschel JC, Finkelstain DM, Ettinger DS, et al (1986). A randomised trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol, 4, 14-22.
  55. Shen RK, Meyers BF, Larner JM, Jones DR (2007). Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd ed). Chest, 132, 290-305. https://doi.org/10.1378/chest.07-1382
  56. Sibel A, Nuray E, Ferah E, et al (2010). Analysis of prognostic factors on stage IIIB-IV, small cell, external lung cancer patients who had chemotherapy. Turk Thorax Magazine, 11, 93-7. https://doi.org/10.5152/ttd.2010.11
  57. Stanley KS (1980). Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst, 65, 25-32.
  58. Sugiura S, Ando Y, Minami H, et al (1997). Prognostic value of pleural effusion in patients with non-small-cell lung cancer. Clin Cancer Res, 3, 47-50.
  59. Taha TB, Nuray BE (2006). Analysis of the survive factors on advantage stage small cell external lung cancer. Med Res Mag, 4, 19-23.
  60. Takigawa N, Segawa Y, Okahara M, et al (1996). Prognostic factors for patients with advanced non-small-cell lung cancer. Lung Cancer, 15, 67-77. https://doi.org/10.1016/0169-5002(96)00571-5
  61. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al (1997). Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Ann Thorac Surg, 36, 1441-50.
  62. Watanabe Y, Shimizu J, Oda M, et al (1991). Results of surgical treatment in patients with stage IIIB non-small-cell lung cancer. Thorac Cardiovasc Surg, 39, 50-4. https://doi.org/10.1055/s-2007-1013930
  63. Wigren T (1997). Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother Oncol, 44, 9-15. https://doi.org/10.1016/S0167-8140(97)00087-X
  64. World Health Organization (1979). Handbook for reporting results of cancer treatment. Publication 48. Geneva (Switzerland): World Health Organization, 1979.
  65. Zuleyha C, Hakan S, Bahattin Y, et al (2011). Analysis of prognostic factors on stage iv, small cell, external lung cancer patients. Acibadem Univ Healthy Sciences Mag, 2, 88-91.

피인용 문헌

  1. Synergistic Effect of Ethaselen and Selenite Treatment against A549 Human Non-small Cell Lung Cancer Cells vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7129
  2. Is there any Potential Clinical Impact of Serum Phosphorus and Magnesium in Patients with Lung Cancer at First Diagnosis? A Multi-institutional Study vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.77
  3. Careful Diagnosis of Aortic Invasion in Patients with Lung Cancer Using Modern Diagnostic Imaging vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.2105
  4. Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer vol.17, pp.1, 2017, https://doi.org/10.1186/s12890-017-0452-0